BioCentury | Apr 8, 2021
Product Development

Next-generation drug conjugates in the spotlight at AACR

...with a radiosensitizing toxin. A team from Washington University in St. Louis...
BioCentury | Apr 8, 2021
Deals

Rounding up intranasal COVID-19 vaccines: Data Byte

...for Epidemic Preparedness Innovations (CEPI) University of Hong Kong Meissa Vaccines Inc. eTheRNA immunotherapies N.V. EpiVax Inc. Bharat Biotech International Ltd. Washington University in St. Louis FluGen...
BioCentury | Feb 23, 2021
Management Tracks

Genmab names Ahmadi CMO, head of experimental medicines; plus moves at Wugen and Aevitas

...director for clinical research at MacroGenics Inc. (NASDAQ:MGNX). Wugen also said Monday that it partnered with Washington University in St. Louis...
BioCentury | Oct 16, 2020
Deals

With Disarm deal, Atlas returns to Lilly to take neuro program forward

...for $135 million up front and $1.2 billion in milestones.Disarm emerged in 2016 from the work of Washington University in St. Louis...
BioCentury | Sep 10, 2020
Product Development

BioNTech, Pfizer complete exploratory talks with the European Commission for 200M COVID-19 vaccine doses

...host cell receptor ACE2. The researchers, which included Washington University in St. Louis...
BioCentury | Aug 28, 2020
Distillery Therapeutics

Vesicular stomatitis virus vector vaccine for COVID-19

...By Claire Quang DISEASE CATEGORY: Infectious diseaseINDICATION: CoronavirusMichael Diamond and colleagues at Washington University in St. Louis showed that immunization...
BioCentury | Aug 1, 2020
Tools & Techniques

A plasma tau marker gains support for diagnosing Alzheimer’s disease

...The second study was published in the Journal of Experimental Medicine by a group at Washington University in St. Louis...
BioCentury | Dec 5, 2019
Emerging Company Profile

VaxNewMo: bioconjugating antibacterial vaccines

...subsequent IP was generated internally. Feldman is now an associate professor of molecular microbiology at Washington University in St. Louis...
BioCentury | Oct 24, 2019
Preclinical News

Oct. 24 Preclinical Quick Takes: anti-neuraminidase human antibodies for broad flu protection; plus Ionis-Baylor, Merck and more

...A Science study from Scripps Research Institute, Icahn School of Medicine at Mount Sinai and Washington University in St. Louis...
...ten; RICTOR - Rapamycin-insensitive companion of mTOR; VEGF - Vascular endothelial growth factor BioCentury Staff Johns Hopkins University Washington University in St. Louis Icahn...
BioCentury | Aug 22, 2019
Financial News

Eyeing new endpoints, Versant-backed Chinook reels in $65M series A for kidney therapies

...human pluripotent stem cells, and newer translational models, including tools developed by Benjamin Humphreys at Washington University in St. Louis...
Items per page:
1 - 10 of 158
BioCentury | Apr 8, 2021
Product Development

Next-generation drug conjugates in the spotlight at AACR

...with a radiosensitizing toxin. A team from Washington University in St. Louis...
BioCentury | Apr 8, 2021
Deals

Rounding up intranasal COVID-19 vaccines: Data Byte

...for Epidemic Preparedness Innovations (CEPI) University of Hong Kong Meissa Vaccines Inc. eTheRNA immunotherapies N.V. EpiVax Inc. Bharat Biotech International Ltd. Washington University in St. Louis FluGen...
BioCentury | Feb 23, 2021
Management Tracks

Genmab names Ahmadi CMO, head of experimental medicines; plus moves at Wugen and Aevitas

...director for clinical research at MacroGenics Inc. (NASDAQ:MGNX). Wugen also said Monday that it partnered with Washington University in St. Louis...
BioCentury | Oct 16, 2020
Deals

With Disarm deal, Atlas returns to Lilly to take neuro program forward

...for $135 million up front and $1.2 billion in milestones.Disarm emerged in 2016 from the work of Washington University in St. Louis...
BioCentury | Sep 10, 2020
Product Development

BioNTech, Pfizer complete exploratory talks with the European Commission for 200M COVID-19 vaccine doses

...host cell receptor ACE2. The researchers, which included Washington University in St. Louis...
BioCentury | Aug 28, 2020
Distillery Therapeutics

Vesicular stomatitis virus vector vaccine for COVID-19

...By Claire Quang DISEASE CATEGORY: Infectious diseaseINDICATION: CoronavirusMichael Diamond and colleagues at Washington University in St. Louis showed that immunization...
BioCentury | Aug 1, 2020
Tools & Techniques

A plasma tau marker gains support for diagnosing Alzheimer’s disease

...The second study was published in the Journal of Experimental Medicine by a group at Washington University in St. Louis...
BioCentury | Dec 5, 2019
Emerging Company Profile

VaxNewMo: bioconjugating antibacterial vaccines

...subsequent IP was generated internally. Feldman is now an associate professor of molecular microbiology at Washington University in St. Louis...
BioCentury | Oct 24, 2019
Preclinical News

Oct. 24 Preclinical Quick Takes: anti-neuraminidase human antibodies for broad flu protection; plus Ionis-Baylor, Merck and more

...A Science study from Scripps Research Institute, Icahn School of Medicine at Mount Sinai and Washington University in St. Louis...
...ten; RICTOR - Rapamycin-insensitive companion of mTOR; VEGF - Vascular endothelial growth factor BioCentury Staff Johns Hopkins University Washington University in St. Louis Icahn...
BioCentury | Aug 22, 2019
Financial News

Eyeing new endpoints, Versant-backed Chinook reels in $65M series A for kidney therapies

...human pluripotent stem cells, and newer translational models, including tools developed by Benjamin Humphreys at Washington University in St. Louis...
Items per page:
1 - 10 of 158